Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Veracyte Inc (NQ: VCYT )

38.50 -0.44 (-1.13%)
Streaming Delayed Price Updated: 10:43 AM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Veracyte Inc

< Previous 1 2 3 4 Next >
Is NASDAQ:VCYT a Fit for high Growth Investing Strategies?
Should you consider VERACYTE INC (NASDAQ:VCYT) for high growth investing? 
Via Chartmill
Smaller Cap Biotechs Are In Season: How Are We Doing?
SMID biotech stocks still see a lot of speculative interest except for a brief sell-off on August 5 when the XBI touched $91.The XBI is near its 2024 high in the $103 range. 
Via Talk Markets
Breaking Down Veracyte: 4 Analysts Share Their Views
Via Benzinga
Tempus AI Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating
A Relative Strength Rating upgrade for Tempus AI shows improving technical performance. 
Via Investor's Business Daily
Topics Artificial Intelligence
Exposures Artificial Intelligence
Thermo Fisher Scientific Stock Sees RS Rating Jump To 81
Thermo Fisher Scientific stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, rising from 77 to 81. 
Via Investor's Business Daily
A Glimpse Into The Expert Outlook On Veracyte Through 4 Analysts
Via Benzinga
Recap: Veracyte Q4 Earnings
Via Benzinga
Earnings Outlook For Veracyte
Via Benzinga
Veracyte: Q3 Earnings Insights
Via Benzinga
Lumen Tech & Upstart Are Among Top 7 Mid Cap Gainers Last Week (Aug 4-Aug 10): Are The Others In Your Portfolio?
Lumen, Upstart, ADMA, Sweetgreen, Veracyte, Clear Secure, and Core Scientific were best performers last week. Did you invest in them? 
Via Benzinga
Diagnostic Tests Maker Veracyte's Q2 Is 'All-Around Very Good Quarter': Analysts Maintain Bullish View
Veracyte reports Q2 sales of $114.43M, a 27% increase year over year, surpassing the $100.3 million consensus. Testing revenue rose 31% to $107 million, driven by strong performance of Decipher... 
Via Benzinga
Shopify Posts Upbeat Earnings, Joins Axon Enterprise, Aspen Technology, Illumina, Global Payments And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Pre-market stock movers are a hot topic on Wednesday and we have all of the latest news traders need to know about them this morning! 
Via InvestorPlace
The Latest Analyst Ratings for Veracyte
Via Benzinga
VCYT Stock Earnings: Veracyte Beats EPS, Beats Revenue for Q2 2024
VCYT stock results show that Veracyte beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
The 3 Best Personalized Nutrition Stocks to Buy Now
Explore personalized nutrition stocks capitalizing on AI, machine learning and genetic profiling to provide targeted dietary solutions. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Trading SMID Biotech Stocks In A Volatile Market
Trading SMID biotech stocks is difficult no matter what you know. Large cap biopharma with dividends should be the focus for non-traders. Healthcare and smaller caps are lagging within the context of a... 
Via Talk Markets
Cathie Wood-Lead Ark Invest Dumps $7.6M Worth Of Robinhood Shares Amid GameStop Buzz, Bitcoin Choppiness
On Monday, Cathie Wood-led Ark Invest made a significant move by reducing its holdings in Robinhood Markets Inc (NASDAQ:HOOD). This decision came amidst a period of market fluctuations and followed a... 
Via Benzinga
VCYT Stock Earnings: Veracyte Beats EPS, Beats Revenue for Q1 2024
VCYT stock results show that Veracyte beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Cathie Wood's Ark Invest Dumps $17M In Coinbase Shares As The Exchange Grappled With Disruption Amid Bitcoin Rally
On Wednesday, Cathie Wood-led Ark Invest made a significant move by selling over $17 million worth of Coinbase Global Inc (NASDAQ:COIN) shares. 
Via Benzinga
Cathie Wood's Ark Invest Sheds $9.3M Worth Of Coinbase Shares Amid Bitcoin Rally — Robinhood Stock Also Sold
On Tuesday, Cathie Wood-led Ark Invest adjusted its portfolio, making significant trades. 
Via Benzinga
Cathie Wood's Ark Invest Offloads $6.9M Worth of Coinbase, Robinhood Shares Each Amid Searing Bitcoin Rally — Nvidia Stock Also Shed
On Monday, Cathie Wood-led Ark Invest adjusted its portfolio, notably selling shares of cryptocurrency-related companies such as Robinhood Markets Inc (NASDAQ:HOOD) and Coinbase Global Inc (NASDAQ: 
Via Benzinga
7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff
Although the health innovation space can be a risky environment, undervalued biotech stocks can take some of the edge off. 
Via InvestorPlace
Cathie Wood's Ark Invest Buys Over $92M Worth Of ProShares Bitcoin ETF, Sells Coinbase, Block And Palantir Shares
On Wednesday, Cathie Wood-led Ark Invest made a significant move in the cryptocurrency space, purchasing over $92 million worth of ProShares Bitcoin Strategy ETF (NYSE:BITO). 
Via Benzinga
Topics ETFs
Are You A Trader Or Investor: Biotech Momentum Is Picking Up
ETFs have not helped as portfolio fillers but they can identify trends. We should play this rally out of a biotech bear market. 
Via Talk Markets
Topics ETFs
7 Undervalued Stocks That Analysts Love Right Now
With many investors concerned about what may lie ahead in the market, these potentially de-risked undervalued stocks may be ideal. 
Via InvestorPlace
Earnings Scheduled For February 22, 2024
Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is likely to report quarterly earnings at $0.28 per share on revenue of $260.00 million. 
Via Benzinga
Earnings Scheduled For November 7, 2023
Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings for its third quarter. 
Via Benzinga
Veracyte Stock Is Volatile After-Hours - Here's Why
Veracyte, Inc. (NASDAQ: VCYT) shares are volatile after-hours on Wednesday after the company announced that new data from a phase 3 trial validates the value of the Decipher Prostate Genomic Classifier... 
Via Benzinga
Is This Underfollowed Genetic Diagnostics Stock a Buy for Growth Investors?
The genetic test maker is rapidly increasing test volumes. 
Via The Motley Fool
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.